Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 11, 2026

Synopsys Outlines Vision for Engineering the Future

View original at finance.yahoo.com
Synopsys Outlines Vision for Engineering the Future Announces new design, verification and simulation solutions to re-engineer AI-powered product innovation at Synopsys Converge 2026 Key Highlights Unveiling Synopsys Multiphysics Fusion™ technology — the first in a broader roadmap of EDA solutions that integrate Synops…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Multiphysics Fusion technology is the first in a broader roadmap of EDA solutions that integrate Synopsys and Ansys technologies for semiconductor design

    60% confidence

  • Synopsys' silicon-to-systems engineering solutions make them the best partner for engineering the future

    60% confidence

  • By integrating co-design of software and hardware, electronics and physics, by harnessing digital twins to design, test, and refine products before physical production, and using AI to enhance human capabilities, customers' R&D teams can accelerate time to market of their intelligent systems

    60% confidence

  • The L4 orchestrated, multi-agent design and verification workflow powered by AgentEngineer technology is an industry-first

    60% confidence

  • The complexity of next-generation intelligent systems requires a completely new engineering approach

    60% confidence

  • The complexity of next-generation intelligent systems requires a completely new engineering approach

    60% confidence

  • The new silicon-to-systems design paradigm for the era of pervasive intelligence is silicon-powered, AI-enabled, and software-defined

    60% confidence

  • Synopsys silicon-to-systems engineering solutions make them the best partner for engineering the future

    60% confidence

  • The complexity of next-generation intelligent systems requires a completely new engineering approach

    60% confidence

  • By integrating co-design of software and hardware, electronics and physics, by harnessing digital twins to design, test, and refine products before physical production, and using AI to enhance human capabilities, customers' R&D teams can accelerate time to market of their intelligent systems

    60% confidence

  • By integrating co-design of software and hardware, electronics and physics, by harnessing digital twins to design, test, and refine products before physical production, and using AI to enhance human capabilities, customers' R&D teams can accelerate time to market of their intelligent systems

    60% confidence

  • Synopsys' silicon-to-systems engineering solutions make them the best partner for engineering the future

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Synopsys Outlines Vision for Engineering the Future — Source | Via News | ViaNews EU